Stakeholders’ involvement in Health Technology Assessment (HTA) can take different forms. Multi-criteria decision analysis (MCDA) offers systematic ways to collect evidence on how stakeholders make trade-offs between decision criteria and to consider this evidence in decision making.

In this study we applied an MCDA framework (EVIDEM V3.0) to derive views and preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and using these to assess the value of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL).

Please note a version of this paper has also been published in PharmacoEconomics (open).